Taken together, dyslipidemia- and inflammation-induced upregulation of IFN-γ receptor, along with elevated IFN-γ in MASLD, likely drive SAMHD1 upregulation in hepatocytes. The gene discussed is SAMHD1; the disease is metabolic syndrome.